局部复发鼻咽癌再程调强放射治疗的疗效及预后分析

doi:10.3969/j.issn.1674-8115.2018.06.014

上海交通大学学报（医学版） ›› 2018, Vol. 38 ›› Issue (6): 662-.doi: 10.3969/j.issn.1674-8115.2018.06.014

局部复发鼻咽癌再程调强放射治疗的疗效及预后分析

张慧慧，张献文，江浩

蚌埠医学院第一附属医院放疗科，蚌埠 233004

出版日期:2018-06-28 发布日期:2018-07-03
通讯作者: 江浩，电子信箱：jianghao1223@163.com。
作者简介:张慧慧（1990—），女，住院医师，硕士生；电子信箱：775186846@qq.com。
基金资助:
安徽省卫生厅“十二五”临床重点专科建设基金（01Z33）

Clinical efficacy and prognostic factors of locally recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy

ZHANG Hui-hui, ZHANG Xian-wen, JIANG Hao

Department of Radiotherapy, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China

Online:2018-06-28 Published:2018-07-03
Supported by:
The“12th Five-Year” Clinical Medical Key Construction Foundation of Anhui Province, 01Z33

摘要/Abstract

摘要： 目的·评价调强放射治疗（intensity-modulated radiotherapy，IMRT）对局部复发鼻咽癌的疗效及不良反应，并进行相关预后分析。方法·将2012年1月—2016年8月共44例诊断为局部复发鼻咽癌且接受再程IMRT患者纳入研究，男33例，女11例，中位年龄51.5岁（25～76岁）。按照《美国癌症联合委员会癌症分期手册》2012版制定的分期标准，将患者划分为4组，其中rT1～rT4的患者分别占25.0%、22.7%、22.7%、29.6%。患者中位复发时间28个月（5～168个月），肿瘤靶区中位处方剂量66 Gy （54～70Gy）。参照美国肿瘤放射治疗协作组织分级标准评估不良反应。用Kaplan-Meier法计算生存率，用Log-rank检验和Cox回归模型进行生存预后相关因素的单因素和多因素分析。结果·再程IMRT结束3个月后完全缓解8例（18.2%）、部分缓解21例（47.7%）、稳定12例（27.3%）、进展3例（6.8%）。随访至2017年9月，全组患者3年生存率、3年总无进展生存率、3年局部无进展生存率和远处转移率分别为56.8%、43.2%、58.9%和11.4%。在单因素分析中，年龄、复发T分期、复发间隔、放射治疗前有/无合并明显并发症及对再程IMRT的反应为总生存率重要预后因素，其中复发T分期亦为无进展生存率的独立预后因素；在多因素分析中，复发T分期为总生存率、无进展生存率及局部无进展生存率的预后因素（均P<0.05）。随访期间死亡21例，5例死于大出血，有12例患者不同部位出现3～4级的不良反应。结论· IMRT为局部复发鼻咽癌有效的补救措施，可有效地提高生存率；但再程IMRT后部分患者出现严重不良反应。年龄较小、复发T分期较早及复发间隔较长是IMRT的良好预后因素。

关键词: 鼻咽癌, 复发, 调强放射治疗, 预后

Abstract:

Objective · To retrospectively analyze the treatment outcome, radiation toxicity and the prognostic factors in patients with locally recurrent nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT). Methods · January 2012 to August 2016, a total of44 patients who were diagnosed with locally recurrent NPC and received reirradiation with IMRT were included in the study. Among all the patients, there were 33 male patients and 11 female patients, the median age of whom was 51.5 years (range 25–76 years). According to the 2012 American Joint Committee on Cancer Stage Classification Cancer Staging Manual, the distribution of disease restaging was 25.0% for stage rT1, 22.7% for stage rT2,22.7% for stage rT3 and 29.6% for stage rT4. The median recurrence interval was 28 months (range 5–168 months). The median prescribed dose to the target volume was 66 Gy (range 54–70 Gy). The toxicities were evaluatedRadiation Therapy Oncology Group (RTOG). The survival rate was determined using the Kaplan-Meier method. Prognostic factors were analyzedLog-rank tests and Cox proportional hazard model. Results · Three months after reirradiation therapy, the complete remission rate, the partial remission rate, the stabilization rate and the progressive rate were 18.2%(8/44), 47.7% (21/44), 27.3% (12/44) and 6.8% (3/44), respectively. The 3-year overall survival (OS), 3-year progression free survival (PFS), 3-year local recurrence-free survival and distant metastasis rates were 56.8%, 43.2%, 58.9% and 11.4%, respectively. In a univariate analysis, age, recurrent T stage, recurrence interval, adverse reactions and response to re-IMRT were significant prognostic factors for OS and recurrent T stage was also an independent prognostic factor for PFS. In a multivariate analysis, recurrent T stage remained significant for OS and PFS. During follow-up, 21 patients died. Five patients died of nasopharynx hemorhea. Grade 3–4 toxicities were reported in 12 patients. Conclusion · Re-irradiation with IMRT is available to improve OS and thus is a reasonable choice for patients with locally recurrent NPC. However, the incidence of severe adverse events is still high. Younger ages lower recurrent T stage and longer recurrent interval are independent prognostic factors for OS of recurrent NPC.

Key words: nasopharyngeal carcinoma, recurrent, intensity-modulated radiotherapy, prognosis

中图分类号:

R739.6

张慧慧，张献文，江浩. 局部复发鼻咽癌再程调强放射治疗的疗效及预后分析[J]. 上海交通大学学报（医学版）, 2018, 38(6): 662-.

ZHANG Hui-hui, ZHANG Xian-wen, JIANG Hao. Clinical efficacy and prognostic factors of locally recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy[J]. , 2018, 38(6): 662-.

[1]	朱嘉莳, 李红, 邵静波, 张娜, 杨静薇, 陈凯, 王真, 蒋慧. 急性淋巴细胞白血病儿童治疗失败原因的分析[J]. 上海交通大学学报(医学版), 2021, 41(6): 764-769.
[2]	程盛, 赵益, 王永琛, 黄平. BRAF基因突变对肝切除后的结直肠癌肝转移患者预后影响的meta分析[J]. 上海交通大学学报(医学版), 2021, 41(6): 786-792.
[3]	陈旭光, 施晟懿, 胡岚, 陈瑜, 陆一鸣, 叶静. 血浆纤维蛋白降解产物对出血性脑卒中患者早期预后的评估价值[J]. 上海交通大学学报(医学版), 2021, 41(5): 612-616.
[4]	陈超, 李聪聪, 郭枫, 王巧红, 赵爱民. 泌乳素在不明原因复发性流产和正常妊娠早期中的差异性表达[J]. 上海交通大学学报(医学版), 2021, 41(4): 489-496.
[5]	包汝娟, 陈慧芳, 董宇, 叶幼琼, 苏冰. 基于转录组异常表达构建结直肠癌特征基因预后风险评分模型[J]. 上海交通大学学报(医学版), 2021, 41(3): 285-296.
[6]	马燕如, 季林华, 童天颖, 严宇青, 沈超琴, 张昕雨, 曹颖颖, 洪洁, 陈豪燕. 基于单细胞RNA测序的结直肠癌预后预测模型的建立和验证[J]. 上海交通大学学报(医学版), 2021, 41(2): 159-165.
[7]	胡培堃, 何杰, 吴连明, 葛恒, 许建荣, 卜军. ST段抬高型心肌梗死患者微血管阻塞对左室功能及预后的影响[J]. 上海交通大学学报(医学版), 2021, 41(2): 173-179.
[8]	傅中懋, 罗再, 戎泽印, 章建明, 李腾飞, 余志龙, 黄陈. 基于高通量测序的结直肠癌组织中环状RNA功能研究与预后分析[J]. 上海交通大学学报(医学版), 2021, 41(2): 187-195.
[9]	邱婷, 靳婧, 崔元玥, 宋蕾, 李谐, 渠继芳. 1例复发性急性髓细胞性白血病眼底出血病例报道[J]. 上海交通大学学报(医学版), 2021, 41(1): 123-125.
[10]	唐冬娟，薛晓梅，何斌. miR-133a对急性心肌梗死的早期诊断及预后评估价值[J]. 上海交通大学学报（医学版）, 2020, 40(3): 339-.
[11]	叶欣，周晓云，杨莉，王杰，何奇. 不同年龄范围界定下的年轻乳腺癌患者的临床病理特征及预后分析[J]. 上海交通大学学报（医学版）, 2020, 40(3): 351-.
[12]	朱正阳1, 2，王成3，姜辰一1，赵福军1, 3, 4. RNA N6- 甲基腺嘌呤异常修饰影响肿瘤干细胞促进恶性肿瘤发生、发展的研究进展[J]. 上海交通大学学报（医学版）, 2020, 40(3): 385-.
[13]	孙思，赵爱民. 复发性流产常用抗凝及抗血小板药物妊娠期暴露的安全性[J]. 上海交通大学学报（医学版）, 2020, 40(3): 402-.
[14]	刘锦燕1，赵珺涛2，王恒如2，黄嘉仪2，王钰婷2，项明洁1, 2. 细胞骨架相关蛋白4对肿瘤诊断和预后的作用[J]. 上海交通大学学报（医学版）, 2020, 40(2): 255-.
[15]	何春明，尹航，唐健，丁一宗，傅于捷，赵晓菁. 基于SEER数据库的老年肺癌术后患者预后模型构建与内部验证[J]. 上海交通大学学报(医学版), 2020, 40(11): 1554-1561.

局部复发鼻咽癌再程调强放射治疗的疗效及预后分析

Clinical efficacy and prognostic factors of locally recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics